Affiliation:
1. University of Electronic Science and Technology of China
2. Sichuan Cancer Hospital & Institute, University of Electronic Science & Technology of China
3. Sun Yat-sen University Cancer Center
Abstract
Abstract
Background
Advanced diffuse large B-cell lymphoma (DLBCL) is a common malignant tumor with aggressive clinical features and poor prognosis. At present, there is lack of effective prognostic tool for patients with advanced (stage III/IV) DLBCL. The aim of this study is to identify prognostic indicators that affect survival and response and establish the first survival prediction nomogram for advanced DLBCL.
Methods
A total of 402 patients with advanced DLBCL were enrolled in this study. COX multivariate analysis was used to obtain independent prognostic factors. The independent prognostic factors were included in the nomogram, and the nomogram to predict the performance of the model was established by R rms package, C-index (consistency index), AUC curve and calibration curve.
Results
The training and validation cohorts included 281 and 121 patients. In the training cohort, multivariate analysis showed that Ki-67 (70% (high expression) vs ≤ 70% (low expression), p < 0.001), LDH (lactate dehydrogenase) (elevated vs normal, p = 0.05), FER (ferritin) (elevated vs normal, p < 0.001), β2-microglobulin (elevated vs normal, p < 0.001) were independent predictors and the nomogram was constructed. The nomogram showed that there was a significant difference in OS among the low-risk, intermediate-risk and high-risk groups, with 5-year survival rates of 81.6%, 44% and 6%, respectively. The C-index of the nomogram in the training group was 0.76. The internal validation of the training group showed good consistency. In the internal validation cohort of the training group, the AUC was 0.828, and similar results were obtained in the validation group, with a C-index of 0.74 and an AUC of 0.803.
Conclusion
The proposed nomogram provided a valuable individualized risk assessment of OS in advanced DLBCL patients.
Publisher
Research Square Platform LLC
Reference31 articles.
1. Diffuse large B-cell lymphoma: current strategies and future directions;Cultrera JL;Cancer Control,2012
2. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution;Yang QP;Diagn Pathol,2011
3. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021;Zelenetz AD;J Natl Compr Canc Netw,2021
4. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Vitolo U;Annals of oncology: official journal of the European Society for Medical Oncology,2016
5. Susanibar-Adaniya, S. and S.K. Barta, 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol, 2021. 96(5): p. 617–629.